Sihuan Pharmaceutical Holdings Group Ltd
Company Profile
Business description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
Contact
Zhubang 2000
22nd Floor, Building 4
West Balizhuang, Chaoyang District
Beijing100025
CHNT: +86 1057693700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,767
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,273.84 | 11.68 | 0.14% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |